Research |
![]() ![]() ![]() ![]() ![]() |
Serial Number | 86148901 |
Registration Number | 4824753 |
Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
Attorney Name | Jennifer A. Van Kirk |
Law Office Assigned | L40 |
Employee Name | HUDSON, TAMARA BREE |
2013-12-19 | Application Filed |
2015-07-21 | Published for Opposition |
2015-10-06 | Location: PUBLICATION AND ISSUE SECTION |
2015-10-06 | Status: Live/Registered |
2015-10-06 | Trademark Registered |
2018-07-08 | Transaction Date |
Owner: | ![]() |
Address | Lago Tanganica No. 18, Colonia Granada Delegacion Miguel Hidalgo Mexico, D.F. MX 11520 |
Legal Entity Type | Corporation |
Legal Entity State | MX |
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
Type Code | Type |
---|---|
GS0051 | Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, endocrinology for treatment of adrenal failure, thyroiditis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely rheumatology for treatment of rheumatoid arthritis, gout, post-traumatic arthritis, osteoarthritis, synovitis, bursitis, epicondylitis, ankylosing spondylitis, systemic or discoid lupus erythematosus, dermatomyositis, scleroderma, other collagen diseases, other osteoarticular diseases which require chronic corticosteroid administration; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory; immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely dermatology for treatment of pemphigus, erythema multiforme, exfoliative dermatitis, psoriasis, contact dermatitis, keloid lesions, hyperthrophic lichen planus, alopecia areata, urticaria, eczema, rosacea; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, allergology for treatment of bronchial asthma, urticaria, drug or food allergy, hypersensitivity reactions, allergic rhinitis, allergic sinusitis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely otolaryngology for treatment of vasomotor rhinitis, other types of rhinitis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, ophthalmology for treatment of allergic, acute or chronic conjunctivitis; scleritis, uveitis/iridocyclitis, optic neuritis, corneal infections, keratitis, marginal ulcers, throphic disorders, conjunctival/corneal physical/chemical burning, inflammatory reactions; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, gastroenterology for treatment of ulcerative colitis, regional enteritis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, pulmonology for treatment of bronchoaspiration, Löeffler syndrome, sarcoidosis, interstitial pulmonary fibrosis, chronic bronchitis, emphysema; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely hematology for treatment of autoimmune anemias or thrombocytopenias, leukemias, lymphomas, intravascular coagulation syndrome; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, oncology for treatment of nausea/vomiting associated with cancer chemotherapy prevention; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, miscellaneous for treatment of shock syndromes, cerebral edema |
Description | Date | Event Coding |
---|---|---|
NEW APPLICATION ENTERED IN TRAM | 2013-12-23 | 1 NWAP I:Incoming Correspondence |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2014-01-07 | 2 NWOS I:Incoming Correspondence |
ASSIGNED TO EXAMINER | 2014-03-26 | 3 DOCK D:Assigned to Examiner |
NON-FINAL ACTION WRITTEN | 2014-04-01 | 4 CNRT R:Renewal |
NON-FINAL ACTION E-MAILED | 2014-04-01 | 5 GNRT F:First Action |
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2014-04-01 | 6 GNRN O:Outgoing Correspondence |
NON-FINAL ACTION WRITTEN | 2014-04-01 | 7 CNRT R:Renewal |
NON-FINAL ACTION E-MAILED | 2014-04-01 | 8 GNRT O:Outgoing Correspondence |
NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2014-04-01 | 9 GNRN O:Outgoing Correspondence |
TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2014-06-05 | 10 TROA I:Incoming Correspondence |
CORRESPONDENCE RECEIVED IN LAW OFFICE | 2014-06-05 | 11 CRFA I:Incoming Correspondence |
TEAS/EMAIL CORRESPONDENCE ENTERED | 2014-06-05 | 12 TEME I:Incoming Correspondence |
ASSIGNED TO EXAMINER | 2014-06-27 | 13 DOCK D:Assigned to Examiner |
EXAMINERS AMENDMENT -WRITTEN | 2014-08-13 | 14 CNEA R:Renewal |
EXAMINERS AMENDMENT E-MAILED | 2014-08-13 | 15 GNEA O:Outgoing Correspondence |
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2014-08-13 | 16 GNEN O:Outgoing Correspondence |
EXAMINER'S AMENDMENT ENTERED | 2014-08-13 | 17 XAEC I:Incoming Correspondence |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2014-08-13 | 18 CNSA P: |
ASSIGNED TO LIE | 2014-08-21 | 19 ALIE A:Allowance for Publication |
LAW OFFICE PUBLICATION REVIEW COMPLETED | 2014-08-22 | 20 PREV O:Outgoing Correspondence |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2014-09-10 | 21 NONP E:E-Mail |
PUBLISHED FOR OPPOSITION | 2014-09-30 | 22 PUBO A:Allowance for Publication |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2014-09-30 | 23 NPUB E:E-Mail |
NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2014-11-25 | 24 NOAM E:E-Mail |
TEAS PETITION TO AMEND BASIS RECEIVED | 2015-05-22 | 25 TPAD I:Incoming Correspondence |
TEAS EXTENSION RECEIVED | 2015-05-22 | 26 EEXT I:Incoming Correspondence |
ASSIGNED TO PETITION STAFF | 2015-05-29 | 27 APET A:Allowance for Publication |
EXTENSION 1 FILED | 2015-05-22 | 28 EXT1 S: |
EXTENSION 1 GRANTED | 2015-06-01 | 29 EX1G S: |
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2015-06-02 | 30 EXRA E:E-Mail |
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | 2015-06-03 | 31 PCBG O:Outgoing Correspondence |
ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED | 2015-06-03 | 32 ATRQ I:Incoming Correspondence |
NOTICE OF ALLOWANCE CANCELLED | 2015-06-15 | 33 IUCN S: |
1(B) BASIS DELETED; NEW BASIS REQUESTED | 2015-06-15 | 34 ADBS I:Incoming Correspondence |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2015-07-01 | 35 NONP E:E-Mail |
PUBLISHED FOR OPPOSITION | 2015-07-21 | 36 PUBO A:Allowance for Publication |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2015-07-21 | 37 NPUB E:E-Mail |
REGISTERED-PRINCIPAL REGISTER | 2015-10-06 | 38 R.PR A:Allowance for Publication |
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | 2020-10-06 | 39 REM1 E:E-Mail |
CANCELLED SEC. 8 (6-YR) | 2022-04-22 | 40 C8.. O:Outgoing Correspondence |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.